Anti-cachectic effects of a novel peptide nucleic acid: Preliminary results of a phase 1/11 clinical trial.
Time: Sunday, June 06, 2004, 1:00pm-5:00pm
Presenter: James T. D'Olimpio, MD
Abstract ID: 8087
Poster Number: U8
Session: Patient Care
Sunday, June 06, 2004, 1:00pm-5:00pm
Location: Hall A (right half)
|HOME | ABOUT ASCO | PRESS CENTER | STATE AFFILIATES | INTERNATIONAL | RESOURCES | SITEMAP | CONTACT US|
I/II study in Cachectic Patients Needing Salvage Therapy for
This seems to be the study that will be presented at the ASCO poster session. How are they tieing this in with cancer? I don't see how they can present the preliminary findings on this trial and claim that it works for cancer patients as well. I guess, I can only conclude that the ASCO conferance isn't just about cancer. Ya think?
Looks to me, from perusing the list of other presentations (a s_hitload), that it would be fairly easy to get lost in the shuffle.
The company needs publicity for it, but will be drowned out by the myriads of other just-as-valuable posters.
This one remind me of 1996 or so when we anticipated huge things from a poster session - and nothing happened. We even had one of us there to report on it. I believe this is somewhat like the presenter stands next to his posters and answers questions of people passing by.
noted that there are many similarities in Quality of Life Issues and
cachexia that are shared by patients with AIDS and cancer.
"Patients suffer from cachexia in both diseases, and in fact,
many patients with AIDS have co-existent cancers, making the situation
even more complex and relevant."
disgusting thing in all this, Jim, is that we HAD a real cancer
cachexia trial scheduled and it was canceled.
Many of us here felt QUITE STRONGLY that if you're going to do cachexia, you should do it with CANCER patients - mainly because CANCER is a big word for the American public and the scientific community.
So....here we are at a CANCER symposium trying to pass off HIV cachexia trial results and qualifying it by saying..."well, CANCER cachexia is similar to cachexia in HIV patients" so that we can sneak into the back door at a CANCER meeting.
This company's management - and this includes their scientists who participate in any administration decisions - is totally screwed up in their thinking process.
And now, after showing their "wares" on HIV at a CANCER meeting, they're trying to tell us it will be good for the company if they do not continue the ALREADY FDA APPROVED PHASE II HPV TRIALS??
Is there something wrong with this picture??
Maybe it's their habit and wisdom to do trials "just to do trials" without any foresight as to what they might do with the results?? Does it seem ridiculous to you that with each and every move forward, ADVR is simply spinning its wheels, trying to fit in ANYWHERE? This company has an identity crisis.
I never understood why we canceled the CANCER trials and went with HIV.
- - - - -
View Replies »
"Dr. D'Olimpio has done extensive research on cachexia, particularly in cancer patients."
In any event, Dr. D'Olimpio does have this poster presentation, so there must be something interesting up his AVR118 sleeve.
is just what I am thinking. The results might be great but, this isn't
about cancer. I don't see how it could claim to be. So, we are going
to a cancer conferance with preliminary results from an HIV trial.
we are at a CANCER symposium trying to pass off HIV cachexia trial
results and qualifying it by saying..."well, CANCER cachexia is
similar to cachexia in HIV patients" so that we can sneak into
the back door at a CANCER meeting. "
Ouro: There's much merit in what you say, but I doubt we're "sneaking in any back door":
YONKERS, N.Y., March 19 /PRNewswire-FirstCall/ -- "Advanced Viral Research Corp. (OTC Bulletin Board: ADVR) announced today that an abstract on AVR118 has been selected for presentation at The American Society of Clinical Oncology's (ASCO) 40th Annual Meeting to be held in New Orleans, LA, June 5-8, 2004. The American Society of Clinical Oncology (ASCO) is the world's leading professional organization representing physicians who treat people with cancer."
I agree with your assessment - but in the end, the title of the
session is Cachexia in HIV patients.
You have to SELL your session to get people to WANT to get to it - and though cachexia IS important, the HIV part will be much harder to pique a cancer specialist's interest to begin with.
Also, Julie, it seems disingenuous to include the "PhaseI/II" part in the title, as we ALL know this moniker has NOTHING to do with the FDA - and in the end will make any serious inquirer ask to himself, "Why did this company try to make this seem as if it is an FDA approved study when in actuality it is not?"
ADVR needs to be straight with the truth, and here we have HIV trial results at a cancer meeting, purportedly seeming as if it is involved in a FDA Phase I/II trial.
Both of these are questionable - and in the end the company's reputation suffers even more than what it is.
elgin- (LFTC) Yes, I am sorry to report that I am a LOOOOOONG
bagholder in that POS......Averaged down once, but just decided that
management wasn't worth another dime.....So, it went into my "POS
- Not likely to go back up, but not worth selling" portion of my
sorry if recognizing the good efforts of those you despise is contrary
to your sense of good will.
Had I said the exact same thing to someone you approve of, you would never had said this.
My attitude is simple - when good is done, it should be recognized.
Your comment does nothing but inspire and reinforce those who don't like you.
Thangs are starting to be better here, must you insert ANYTHING that will disrupt the fragile peace??
As far as potty training, right now YOU are my focus.
Dr. D'Olimpio wanted badly to present something at the ASCO National
meeting, being a member of the association, and the only research he's
involved with and could hang his hat on was the Israel cachexia trials
with which he was tangentially associated, as
"spokesperson-at-large" for the company. So it gives
D'Olimpio a chance to present a paper and add to his curriculum vitae,
and it gives ADVR a little publicity for the drug in a national forum.
I guess that can be construed as a win-win proposition of some sort.
If the Israeli cancer cachexia trials hadn't been cancelled at the
recommendation of good old Nowinski last year, there would probably be
have been really relevant data on cancer cachexia to report as well.
- - - - -
will be attending the symposiums small cap equities conferance on June
2nd at the Roosevelt Hotel in New York city.
Anybody know anything about this and what they will be doing there?
although I haven't read all the posts here on this subject as I'm busy
with other things, but I have read the main ones I'm sure. There's
merit to all of them and good points have been made, [and repeated].
I'm still in a "wait and see" mode and as I said in my post to Jim:
"In any event, Dr. D'Olimpio does have this poster presentation, so there must be something interesting up his AVR118 sleeve."
As usual, I'm always taking the positive road and hope it leads me to not being disappointed.
the Israeli physicians who actually did the AIDS cachexia trials and
actually treated and examined the patients be the ones to present their
data at a conference? If D'Olimpio is asked questions by physicans
attending the poster session regarding pateint specifics, will he be
able to answer as well as the actual doctors who did the study ? To my
knowledge, D'Olimpio did not fly to Israel to meet with the patients and
doctors during the trials and review the individual patient charts with